XNW4107 not checked

Evopoint Biosciences Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
6 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for Injection”In the company’s words, NCT05204563 on ClinicalTrials.gov
Tested for
Bacterial Infections (4 trials), Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia, Complicated Urinary Tract Infection Including Acute Pyelonephritis
Main trialPhase 3
“This study aims to compare treatment with Imipenem/Cilastatin-XNW4107 (IMI-XNW4107) with imipenem/cilastatin/relebactam (IMI/REL) in participants with hospital-acquired or ventilator-associated bacterial pneumonia (HABP or VAPB, respectively). The primary hypothesis is that IMI-XNW4107 is non-inferior to IMI/REL in all-cause mortality.”In the company’s words, NCT05204563 on ClinicalTrials.gov

Other drugs for Bacterial Infections

All 125 drugs for Bacterial Infections

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Completed 29 Sep 2024 Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)
Phase 3Unknown Jun 2025 Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)
Phase 1Completed 28 Feb 2021 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin
Phase 1Completed 15 May 2021 Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects
Phase 1Completed 30 Oct 2021 Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function
Phase 1Completed 30 Oct 2021 To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow XNW4107

Following is part of Solo: you see every change to XNW4107 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in